Biomatters Opens Two US Offices To Support Geneious Customer Growth

Newark, NJ (PRWEB) September 12, 2011

Global scientific software company Biomatters has opened its first US offices in Newark, NJ and San Francisco, CA, in response to growing customer demand from commercial, government and academic research institutions for its Geneious Pro and Geneious Server software. The two offices will cover all of North America from coast to coast, and provide rapid high-quality customer support across all North American time zones. Additional professional services such as onsite training, custom installation support options and custom development will also be available.

The rapid growth in commercial and large-scale institutional research customers in particular have driven the need for North American key account managers and sales teams. "We've always enjoyed close collaborative relationships with all our Geneious customers," says Dr. Peter Meintjes, Biomatters' Market Development Manager. "An account managed approach for larger research organizations means we can stay close to their changing requirements and better cater for them in future versions of Geneious."

The launch of Geneious Server last year, which allows high intensity computing such as NGS data to be offloaded to servers and supercomputers, has also increased institutional and commercial demand. "Worldwide sales of Geneious have grown tremendously over the last few years, including 297% growth for the last New Zealand Fiscal year as recorded by the Deloitte Fast 50" says Meintjes. "Geneious originally spread quickly through individual academic users, but institutional site-wide commercial sales are now the fastest growing part of our business."

Geneious customers include several major government departments such as the National Institutes of Health, Centers for Disease Control and Prevention, The Smithsonian Institution and US Department of Agriculture. It is used at all of the world's top 25 universities as listed by the Time Higher Education guide, and has the fastest growing citation rate of any sequence analysis software. "Our growth has been fueled by institutions realizing that they need to invest as much in workflow and analysis tools that improve teamwork as they do in hardware if they want to improve their speed of discovery," says Meintjes.

The US offices will be led by two new Sales Directors.

Luke Brennan joins Biomatters as Eastern Region Sales from Genomatix Software Inc. where he was Director of Eastern Region Sales. He has over 20 years experience in selling biotechnology and bioinformatics products in the USA and is a specialist in NGS data analysis, imaging and image analysis, histopathology, biomarker discovery and other disciplines. To connect with Luke to discuss your bioinformatics needs, email luke(at)biomatters(dot)com.

Kashef joins Biomatters from IO informatics where he was Director of Business Development. He has over 10 years experience in pharma and biotechnology sales and business development and is a specialist in bioinformatics, genomics and proteomics. To connect with Kashef to discuss your bioinformatics needs, email kashef(at)biomatters(dot)com.

About Biomatters, Ltd.
Biomatters is a privately-held scientific software company, with offices in Newark, San Francisco and headquarters in Auckland, New Zealand.

Biomatters creates software that can be used by all researchers in their daily work, including the popular Geneious Pro and Geneious Server tools. Biomatters' technology converts raw data into meaningful, visual information, simplifying research, accelerating biological research and ultimately improving efficiency.

Read more: http://www.digitaljournal.com/pr/417340#ixzz1XvQ600KG

 

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.